Genesis of derivative chromosome 9 deletions in chronic myeloid leukemia
2005; Wiley; Volume: 43; Issue: 2 Linguagem: Inglês
10.1002/gcc.20163
ISSN1098-2264
Autores Tópico(s)Acute Myeloid Leukemia Research
ResumoGenes, Chromosomes and CancerVolume 43, Issue 2 p. 223-224 Letters to the Editors Genesis of derivative chromosome 9 deletions in chronic myeloid leukemia Alistair G. Reid, Alistair G. Reid Department of Academic Haematology,Royal Free and University College School of Medicine, London,United KingdomSearch for more papers by this authorEllie P. Nacheva, Corresponding Author Ellie P. Nacheva [email protected] Department of Academic Haematology,Royal Free and University College School of Medicine, London,United KingdomUniversity College London, Department of Academic Haematology, Royal Free and University College School of Medicine, Rowland Hill Street, London NW3 2PFSearch for more papers by this author Alistair G. Reid, Alistair G. Reid Department of Academic Haematology,Royal Free and University College School of Medicine, London,United KingdomSearch for more papers by this authorEllie P. Nacheva, Corresponding Author Ellie P. Nacheva [email protected] Department of Academic Haematology,Royal Free and University College School of Medicine, London,United KingdomUniversity College London, Department of Academic Haematology, Royal Free and University College School of Medicine, Rowland Hill Street, London NW3 2PFSearch for more papers by this author First published: 04 March 2005 https://doi.org/10.1002/gcc.20163Citations: 3Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES Buno I, Wyatt WA, Zinsmeister AR, Dietz-Band J, Silver RT, Dewald GW. 1998. A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood 92: 2315–2321. CASPubMedWeb of Science®Google Scholar Chase A, Grand F, Zhang JG, Blackett N, Goldman J, Gordon M. 1997. Factors influencing the false positive and negative rates of BCR–ABL fluorescence in situ hybridization. Genes Chromosomes Cancer 18: 246–253. 10.1002/(SICI)1098-2264(199704)18:4 3.0.CO;2-0 CASPubMedWeb of Science®Google Scholar Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, Trakhtenbrot L. 2001. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128: 114–119. 10.1016/S0165-4608(01)00412-5 CASPubMedWeb of Science®Google Scholar de la Fuente J, Merx K, Steer EJ, Muller M, Szydlo RM, Maywald O, Berger U, Hehlmann R, Goldman JM, Cross NC, Melo JV, Hochhaus A. 2001. ABL–BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 98: 2879–2880. 10.1182/blood.V98.9.2879 CASPubMedWeb of Science®Google Scholar Herens C, Tassin F, Lemaire V, Beguin Y, Collard E, Lampertz S, Croisiau C, Lecomte M, De Prijk B, Longree L, Koulischer L. 2000. Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol 110: 214–216. 10.1046/j.1365-2141.2000.02142.x CASPubMedWeb of Science®Google Scholar Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, Szer J, Prince HM, Turner P, Grace C, Nacheva EP, Green AR. 2001. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98: 1732–1738. 10.1182/blood.V98.6.1732 CASPubMedWeb of Science®Google Scholar Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, Squire JA. 2001. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97: 3581–3588. 10.1182/blood.V97.11.3581 CASPubMedWeb of Science®Google Scholar Le Gouill S, Talmant P, Milpied N, Daviet A, Ancelot M, Moreau P, Harousseau JL, Bataille R, Avet-Loiseau H. 2000. Fluorescence in situ hybridization on peripheral-blood specimens is a reliable method to evaluate cytogenetic response in chronic myeloid leukemia. J Clin Oncol 18: 1533–1538. CASPubMedWeb of Science®Google Scholar Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, She CJ, Yoon SS, Shin HR, Kim Y, Cho HI. 2003. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes Chromosomes Cancer. 37: 291–299. 10.1002/gcc.10197 CASPubMedWeb of Science®Google Scholar Loncarevic IF, Romer J, Starke H, Heller A, Bleck C, Ziegler M, Fiedler W, Liehr T, Clement JH, Claussen U. 2002. Heterogenic molecular basis for loss of ABL1–BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR–ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 34: 193–200. 10.1002/gcc.10056 CASPubMedWeb of Science®Google Scholar Muller C, Hennig E, Franke C, Krahl R, Leiblein S, Niederwieser D, Deininger MW. 2002. The BCR/ABL-extra signal fluorescence in situ hybridization system reliably detects deletions upstream of the ABL locus: implications for reporting of results and followup of chronic myelogenous leukemia patients. Cancer Genet Cytogenet 136: 149–150. Google Scholar Najfeld V. 2002. High performance of the BCR/ABL–extra sensitive (ES) probe for detection of der(9q) deletion in t(9;22)(q34;q11.2). Cancer Genet Cytogenet 132: 171. Google Scholar Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. 2003. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukemia. Br J Haematol 121: 419–427. 10.1046/j.1365-2141.2003.04291.x PubMedWeb of Science®Google Scholar Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, Bench A, Champion K, Huntly B, Green AR. 2000. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95: 738–743. 10.1182/blood.V95.3.738.003k21_738_743 CASPubMedWeb of Science®Google Scholar Storlazzi CT, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, Rocchi M, Liso V. 2002. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 35: 271–276. 10.1002/gcc.10116 CASPubMedWeb of Science®Google Scholar Citing Literature Volume43, Issue2June 2005Pages 223-224 ReferencesRelatedInformation
Referência(s)